Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2020 11/24/2020 11/25/2020 11/27/2020 11/30/2020 Date
101.03(c) 98.56(c) 109.18(c) 127.03(c) 149.83 Last
16 359 624 12 515 336 25 850 691 43 438 495 65 134 076 Volume
+3.50% -2.44% +10.78% +16.35% +17.95% Change
More quotes
Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash position 2020 2 547 M - -
P/E ratio 2020 -86,2x
Yield 2020 -
Sales 2021 6 272 M - -
Net income 2021 1 749 M - -
Net cash position 2021 5 267 M - -
P/E ratio 2021 30,5x
Yield 2021 -
Capitalization 50 267 M 50 267 M -
EV / Sales 2020 106x
EV / Sales 2021 7,17x
Nbr of Employees 1 100
Free-Float 90,0%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
Sector
Biotechnology & Medical Research
Calendar
12/01 | 12:30pmPresentation
More about the company
Notations Surperformance© of Moderna, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MODERNA, INC.
03:34pMODERNA : Moody's says most sovereigns face 'significant negative shock' from CO..
RE
03:30pMODERNA : TREASURIES-Yield curve slightly steeper despite month-end rebalancing
RE
01:07pGlobal stock markets slide; but on pace for best month ever
RE
01:02pGlobal stock markets slide; but on pace for best month ever
RE
01:01pVIRUS TODAY : Vaccine gains momentum, NFL season in chaos
AQ
12:11pMODERNA : U.S. records 140K new COVID-19 cases as air traffic sets pandemic high
AQ
11:40aANALYSIS : Small caps set to keep surging as vaccines aid recovery
RE
11:10aMODERNA : TREASURIES-Yield curve steepens ahead of month-end rebalancing
RE
10:57aWall Street retreats, S&P 500 still set for best November ever
RE
10:47aAmerican Airlines conducts trials to transport COVID-19 vaccine
RE
10:36aModerna to seek U.S. and EU authorization for its vaccine on Monday
RE
10:15aMODERNA : Stocks fall as Wall Street puts quiet stamp on rocking month
AQ
09:51aGlobal stock markets set for best month ever; gold and dollar pay the price
RE
08:43aGLOBAL MARKETS LIVE: Moderna, Novax, S&P Global
08:32aStocks set for best month ever, dollar and gold pay the price
RE
More news
News in other languages on MODERNA, INC.
03:08pL'Opep remet à mardi ses discussions sur les coupes de production d'or noir
01:37pCapitalisation record à Wall Street pour la petite biotech Moderna
12:58pEUROPE : Les marchés européens reculent après un mois en fanfare
12:23pBourse de Paris: prises de bénéfices ternissent
12:18pAKTIEN WIEN SCHLUSS : ATX mit starkem Börsenmonat November
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 11/20
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 110,59 $
Last Close Price 127,03 $
Spread / Highest target 30,7%
Spread / Average Target -12,9%
Spread / Lowest Target -52,8%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493
IMMUNOMEDICS, INC.315.22%20 324